360 NEWS360 NEWS
Home / Business

Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion

Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest move in its acquisition spree as it expands into cancer and autoimmune diseases.

Published
Original News Source Bloomberg — Business
Content & Media Rights Deirdre Hipwell / Bloomberg — Business
Editorial Publisher 360 NEWS (Independent Media)
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest move in its acquisition spree as it expands into cancer and autoimmune diseases.

Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].